The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging
Open accessAbstract
Smart molecular probes for both diagnostic and therapeutic purposes are expected to provide significant advances in clinical medicine and biomedical research. We describe such a probe that targets beta-amyloid plaques of Alzheimer's disease and is detectable by magnetic resonance imaging (MRI) because of contrast imparted by gadolinium labeling. Three properties essential for contrast enhancement of beta-amyloid plaques on MRI exist in this smart molecular probe, putrescine-gadolinium-amyloid-beta peptide: (1) transport across the blood-brain barrier following intravenous injection conferred by the polyamine moiety, (2) binding to plaques with molecular specificity by putrescine-amyloid-beta, and (3) magnetic resonance imaging contrast by gadolinium. MRI was performed on ex vivo tissue specimens at 7 T at a spatial resolution approximating plaque size (62.5 microm(3)), in order to prove the concept that the probe, when administered intravenously, can selectively enhance plaques. The plaque-to-background tissue contrast-to-noise ratio, which was precisely correlated with histologically stained plaques, was enhanced more than nine-fold in regions of cortex and hippocampus following intravenous administration of this probe in AD transgenic mice. Continuing engineering efforts to improve spatial resolution are underway in MRI, which may enable in vivo imaging at the resolution of individual plaques with this or similar contrast probes. This could enable early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Cited by
Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers
Wahsner, J., Gale, E. M., Rodríguez-Rodríguez, A., & Caravan, P. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00363 · Cited by 1,603
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Self-citationClassification and basic properties of contrast agents for magnetic resonance imaging
Geraldes, C. F. G. C., & Laurent, S. (2009) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.265 · Cited by 541
PET imaging of amyloid in Alzheimer's disease
Nordberg, A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00853-1 · Cited by 464
Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders
DeKosky, S. T., & Marek, K. (2003) · Science · doi:10.1126/science.1090349 · Cited by 406
In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe
Hintersteiner, M., Enz, A., Frey, P., Jaton, A.-L., Kinzy, W., Kneuer, R., Neumann, U., Rudin, M., Staufenbiel, M., Stoeckli, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1085 · Cited by 341
19F and 1H MRI detection of amyloid β plaques in vivo
Higuchi, M., Iwata, N., Matsuba, Y., Sato, K., Sasamoto, K., & Saido, T. C. (2005) · Nature Neuroscience · doi:10.1038/nn1422 · Cited by 339
Modo, M., Hoehn, M., & Bulte, J. W. M. (2005) · Molecular Imaging · doi:10.1162/15353500200505145 · Cited by 294
Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging
Wadghiri, Y. Z., Sigurdsson, E. M., Sadowski, M., Elliott, J. I., Li, Y., Scholtzova, H., Tang, C. Y., Aguinaldo, G., Pappolla, M., Duff, K., et al. (2003) · Magnetic Resonance in Medicine · doi:10.1002/mrm.10529 · Cited by 280
Self-citationGong, N.-J., Dibb, R., Bulk, M., van der Weerd, L., & Liu, C. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.02.019 · Cited by 162
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
In Vivo Magnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice
Jack, C. R., Wengenack, T. M., Reyes, D. A., Garwood, M., Curran, G. L., Borowski, B. J., Lin, J., Preboske, G. M., Holasek, S. S., Adriany, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2588-05.2005 · Cited by 148
Self-citationTransgenic mouse models of Alzheimer's disease: phenotype and application.
(2003) · PubMed · doi:10.1097/01.fbp.0000088420.18414.ff · Cited by 147
“Mouse models of amyloidosis, including the PDAPP, Tg2576 and PSAPP, lines are now being used in this optimization process (Skovronsky et al., 2000; Bacskai et al., 2001; Kung et al., 2002; Lee et al., 2002; Poduslo et al., 2002).”
BackgroundMethodIn Vivo mouse imaging and spectroscopy in drug discovery
Beckmann, N., Kneuer, R., Gremlich, H., Karmouty‐Quintana, H., Blé, F., & Müller, M. (2007) · NMR in Biomedicine · doi:10.1002/nbm.1153 · Cited by 118
Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057097 · Cited by 114
Li, Y., Xu, D., Ho, S.-L., Li, H.-W., Yang, R., & Wong, M. S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.047 · Cited by 102
A review of β-amyloid neuroimaging in Alzheimer's disease
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93
Quantitative magnetic resonance techniques as surrogate markers of Alzheimer’s disease
Kantarci, K., & Jack, C. R. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.196 · Cited by 80
Self-citationAPP transgenic mice: their use and limitations
Balducci, C., & Forloni, G. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8141-7 · Cited by 79
“Several groups have used MRI to document amyloid plaque pathology progression in humans and mice (Benveniste et al. 1999; Dhenain et al. 2002; Poduslo et al. 2002; Jack et al. 2004; Lee et al. 2004; Falangola et al. 2005; Vanhoutte et al. 2005; Jack et al. 2007; Wengenack et al. 2008).”
Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain
Wengenack, T. M., Reyes, D. A., Curran, G. L., Borowski, B. J., Lin, J., Preboske, G. M., Holasek, S. S., Gilles, E. J., Chamberlain, R., Marjanska, M., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.08.033 · Cited by 41
Self-citationDudeffant, C., Vandesquille, M., Herbert, K., Garin, C. M., Alves, S., Blanchard, V., Comoy, E. E., Petit, F., & Dhenain, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-05285-1 · Cited by 34
Alzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27
Santin, M. D., Vandenberghe, M. E., Herard, A.-S., Pradier, L., Cohen, C., Debeir, T., Delzescaux, T., Rooney, T., & Dhenain, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00055 · Cited by 20
Mouse models of neurodegenerative disease: preclinical imaging and neurovascular component
Albanese, S., Greco, A., Auletta, L., & Mancini, M. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9770-3 · Cited by 16
Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer’s disease
Zhou, C., Zeng, F., Yang, H., Liang, Z., Xu, G., Li, X., Liu, X., & Yang, J. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06690-1 · Cited by 14
Metadata
- Authors
- Poduslo, J. F., Wengenack, T. M., Curran, G. L., Wisniewski, T., Sigurdsson, E. M., Macura, S. I., Borowski, B. J., & Jack, C. R.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2002-11
- Volume
- 11
- Issue
- 2
- Pages
- 315-329
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2007284815
- Cited by
- 215
- References
- 1
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.